Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cleo Diagnostics's operating assets for the quarter that ended in Dec. 2025 was A$0.54 Mil. Cleo Diagnostics's operating liabilities for the quarter that ended in Dec. 2025 was A$1.14 Mil. Cleo Diagnostics's Total Assets for the quarter that ended in Jun. 2025 was A$6.94 Mil. Therefore, Cleo Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -0.09.
Cleo Diagnostics Scaled Net Operating Assets Related Terms
Cleo Diagnostics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Cleo Diagnostics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleo Diagnostics Scaled Net Operating Assets Chart
ASX:COV vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Cleo Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.09 mean?
Cleo Diagnostics (ASX:COV) has a Scaled Net Operating Assets of -0.09 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Scaled Net Operating Assets too high?
Cleo Diagnostics' current Scaled Net Operating Assets is -0.09. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Scaled Net Operating Assets compare to ABT and SYK?
Cleo Diagnostics' Scaled Net Operating Assets of -0.09 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Scaled Net Operating Assets is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Scaled Net Operating Assets of -0.09. The current Scaled Net Operating Assets is -0.09. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Scaled Net Operating Assets is -0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score
Get the complete analysis for ASX:COV
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 